Medicinal application of CREG protein in preventing or treating overweight, obesity and related diseases thereof

一种蛋白、肥胖的技术,应用在E1A激活基因阻遏子领域,能够解决作用及其机制不清楚等问题

Inactive Publication Date: 2018-02-16
GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the role of CREG proteins on obesity and related diseases and its mechanism are still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1. Preparation of obesity model of C57BL / 6J mice fed with high fat and detection of CREG protein expression in adipose tissue.

[0050] ①Establishment of obesity model in C57BL / 6J mice.

[0051] Using random table method, 40 male 8-week-old C57BL / 6 mice [body weight (22.3±1.2) g] were divided into the following two groups: normal feeding group and high-fat feeding group, 20 mice in each group. The normal feeding group is fed with normal diet feed (3.85kcal / g, fat provides 10% of calories, U.S. Research Diet company), and the high-fat feeding group is fed with high-fat feed (5.24kcal / g, fat provides 60% of calories, U.S. Research Diet company). Continue feeding for 16 weeks. The mice were fed with standard feeding conditions, received 12 hours of light, and did not limit the amount of food and water they drank.

[0052] The results show that: after feeding for 16 weeks, observe the general shape of the mice, and find that the mice in the high-fat feeding group...

Embodiment 2

[0071] Example 2: CREG protein treatment significantly reduces obesity in high-fat fed C57BL / 6J mice.

[0072] ① CREG protein treatment can reduce obesity in mice induced by high-fat feeding.

[0073]Using the random table method, 60 male 8-week-old C57BL / 6 mice were divided into the following three groups: normal feeding group, high-fat feeding group, high-fat feeding + CREG protein treatment group. 20 in each group. Normal feeding and high-fat feeding methods are the same as in Example 1. In the high-fat feeding + CREG protein treatment group, at the same time as high-fat feeding, the mice were treated with CREG protein (Abcam, USA, 150 μg / kg·d) by subcutaneously embedding a micro-osmotic pump (Alzet, USA) for 16 week. The mice were fed with standard feeding conditions, received 12h of light, and did not limit the amount of food and water they drank. After 16 weeks, the general morphology of the mice was observed.

[0074] The results showed that after high-fat feeding,...

Embodiment 3

[0096] Example 3: CREG protein treatment significantly alleviated fatty degeneration in the liver of C57BL / 6J mice fed with high fat.

[0097] ①HE staining of the liver tissues of mice in the three groups.

[0098] When feeding for 16 weeks, the liver tissues of the mice in each group were taken for HE staining, and the specific method was the same as in Example 2.

[0099] The results showed that, compared with the normal-fed control group mice, the high-fat-fed mice had significant fatty degeneration in the liver, and the liver cells were occupied by a large number of lipid droplets. Compared with the mice in the high-fat-fed group alone, the degree of hepatocyte steatosis was significantly reduced after the mice in the high-fat-fed group were treated with CREG protein (for the results, see image 3 A), showing that CREG treatment antagonizes obesity-associated fatty liver in mice.

[0100] ②Comparison of liver tissue weight in three groups of mice.

[0101] After feeding...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of cellular repressor of E1A-stimulated gene (CREG) protein, and in particular to an application of the CREG protein or an active fragment thereof in preparingmedicines for preventing and / or treating overweight, obesity, insulin resistance, hyperlipemia and related diseases thereof. The invention also relates to an application of a recombinant vector or recombinant cells of the CREG protein or the active fragment thereof in preventing and / or treating overweight, obesity, insulin resistance, hyperlipemia and related diseases thereof.

Description

technical field [0001] The present invention relates to the medical application of E1A activated gene repressor (Cellular Repressor of E1A-stimulated Genes, CREG), in particular to the preparation of CREG protein or its active fragments for preventing or treating overweight, obesity, insulin resistance, hyperlipidemia and the like. The use of drugs for related diseases. Background technique [0002] Overweight and obesity are chronic metabolic diseases characterized by excessive accumulation or abnormal distribution of fat. According to body mass index (body weight index, BMI = weight / height 2 ), the World Health Organization defines BMI ≥ 25Kg / m 2 Defined as overweight, BMI ≥ 30Kg / m 2 Defined as obesity, the domestic standard is: BMI≥24Kg / m 2 Defined as overweight, BMI ≥ 28Kg / m 2 Defined as obesity, overweight can develop into obesity if it cannot be controlled in time. Overweight and obesity are both an independent disease and can be accompanied or secondary to a var...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P3/04A61P3/06A61P5/50
CPCA61K38/1709A61P3/06A61P3/04A61P5/50A61P3/08A61P1/16A61K38/17
Inventor 韩雅玲田孝祥闫承慧张权宇张效林刘丹
Owner GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products